Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Summary

This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care. In this clinical trial, rtPA will be injected intravenously using an infusion device. If reperfusion is not occur in spite of rtPA therapy, endovascular therapy can be performed.

Timeline

Start

2019-03-18

Primary completion

2020-10-19

Completion

2020-12-18

Drugs

Indications